Merck & Co., Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
Merck & Co., Inc. (MRK) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $0 for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2019-05-08
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2018-09-30 was $0.00.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2018-03-31 was $8.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month |
|---|---|---|---|
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $8.00M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $8.00M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $8.00M 10-Q · filed 2019-05-08 | ||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $3.00M derived: sum of 2 quarters · filed 2018-11-06 | $3.00M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $3.00M 10-Q · filed 2018-08-07 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-08 | ||
| 2016-09-30 | $223.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $223.00M derived: sum of 2 quarters · filed 2017-11-07 | $300.00M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $77.00M 10-Q · filed 2017-08-08 | |
| 2016-03-31 | $77.00M 10-Q · filed 2017-05-09 | ||
| 2015-09-30 | $105.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $105.00M derived: sum of 2 quarters · filed 2016-11-07 | $228.00M 10-Q · filed 2016-11-07 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $123.00M 10-Q · filed 2016-08-08 | |
| 2015-03-31 | $123.00M 10-Q · filed 2016-05-09 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |